Lancet study shows mixing vaccines is highly effective against Covid
People who received a first dose of the Oxford-AstraZeneca COVID-19 vaccine followed by an mRNA vaccine shot had a lower risk of infection compared to those immunised with both doses of the AstraZeneca preventive, according to a nationwide study in Sweden.
AstraZeneca Pharma India Ltd - 506820 - Shareholding for the Period Ended September 30, 2021
AstraZeneca Pharma India Ltd has submitted to BSE the Shareholding Pattern for the Period Ended September 30, 2021. For more details, kindly Click here ASTRAZENECA PHARMA INDIA LTD. - 506820 - Statement Of Investor Complaints For The Quarter Ended September 2021
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0110 Name of the Signatory :- PRATAP RUDRADesignation :- Company Secretary and Compliance Officer ASTRAZENECA PHARMA INDIA LTD. - 506820 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Pursuant to Regulation 39(3) and other applicable regulations of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform you that the Registrar and Transfer Agents of the Company, Integrated Registry Management Services Private Limited have informed the Company on the attached request for loss of share certificate from the claimant ASTRAZENECA PHARMA INDIA LTD. - 506820 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
We are enclosing herewith Certificate dated October 6, 2021 issued by Integrated Registry Management Services Private Limited, Registrar and Transfer Agents (RTA) of the Company confirming the compliance of Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018.
AstraZeneca COVID-19 drug cocktail succeeds in late-stage trial
The drug, called AZD7442, reduced the risk of developing severe COVID-19 or death by 50% in patients who had been symptomatic for seven days or less, meeting the main goal of the trial. AstraZeneca asks FDA to authorise Covid antibody treatment
Late-stage human trials showed that AZD7442 reduced the risk of developing symptomatic Covid-19 by 77 per cent
'I got Covishield from India': President of the 76th UN General Assembly Abdulla Shahid
The Covishield vaccine, which has been developed by British-Swedish pharmaceutical company AstraZeneca, is manufactured in India by Pune-based Serum Institute of India.
Australia drugs regulator approves India-made AstraZeneca vaccine for Covid
China-made vaccine recognised as well as Australia starts to unwind some of the world's most intense pandemic border restrictions. ASTRAZENECA PHARMA INDIA LTD. - 506820 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Pursuant to Regulation 39(3) and other applicable regulations of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform you that the Registrar and Transfer Agents of the Company, Integrated Registry Management Services Private Limited have informed the Company on the attached request for loss of share certificate from the claimant.